The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Managing immune-related adverse events in patients with HCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, addresses the serious challenge of immune-related adverse events in patients with liver cancer receiving immunotherapy. Grade 3-4 hepatitis occurs in 10-20% of patients, requiring high-dose steroids for worsening liver function. Patients with baseline liver dysfunction face increased risk of liver failure despite prompt steroid treatment. Prof. Lam Chan emphasizes the critical need for early identification and aggressive treatment of these adverse events. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
